Showing 1 - 10 results of 10 for search 'Edgar Faber', query time: 0.06s Refine Results
  1. 1
    Infectious complications of induction treatment for acute myeloid leukaemia using the "7 + 3" protocol without antibiotic prophylaxis - 15 years of experience of one clinical site

    Infectious complications of induction treatment for acute myeloid leukaemia using the "7 + 3" protocol without antibiotic prophylaxis - 15 years of experience of one clinical site by Martin Cernan, Tomas Szotkowski, Jaromir Hubacek, Milan Kolar, Edgar Faber, Karel Indrak, Tomas Papajik

    Published 2023-09-01
    Get full text
    Article
  2. 2
    Enlarged memory T-cell pool and enhanced Th1-type responses in chronic myeloid leukemia patients who have successfully discontinued IFN-α monotherapy.

    Enlarged memory T-cell pool and enhanced Th1-type responses in chronic myeloid leukemia patients who have successfully discontinued IFN-α monotherapy. by Mette Ilander, Anna Kreutzman, Peter Rohon, Teresa Melo, Edgar Faber, Kimmo Porkka, Jukka Vakkila, Satu Mustjoki

    Published 2014-01-01
    Get full text
    Article
  3. 3
    Treatment with low-dose tyrosine kinase inhibitors due to significant haematologic toxicity in patients with CML with prolonged treatment failure prevents haematologic progression

    Treatment with low-dose tyrosine kinase inhibitors due to significant haematologic toxicity in patients with CML with prolonged treatment failure prevents haematologic progression by Lucia Vráblová, Hana Klamová, Ivana Skoumalová, Jana Navrátilová, Romana Janská, Jan Grohmann, Milena Holzerová, Edgar Faber

    Published 2024-12-01
    Get full text
    Article
  4. 4
    Spontaneous splenic rupture in a patient with acute promyelocytic leukaemia during induction chemotherapy

    Spontaneous splenic rupture in a patient with acute promyelocytic leukaemia during induction chemotherapy by Adam Kuba, Tomas Szotkowski, Peter Rohon, Edgar Faber, Peter Turcsanyi, Jaromir Hubacek, Milena Holzerova, Vojtech Prasil, Marie Jarosova, Karel Indrak

    Published 2015-06-01
    Get full text
    Article
  5. 5
    Interferon-α Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients.

    Interferon-α Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in Hi... by Vaclava Polivkova, Peter Rohon, Hana Klamova, Olga Cerna, Martina Divoka, Nikola Curik, Jan Zach, Martin Novak, Iuri Marinov, Simona Soverini, Edgar Faber, Katerina Machova Polakova

    Published 2016-01-01
    Get full text
    Article
  6. 6
    Chronic myeloid leukemia patients in prolonged remission following interferon-α monotherapy have distinct cytokine and oligoclonal lymphocyte profile.

    Chronic myeloid leukemia patients in prolonged remission following interferon-α monotherapy have distinct cytokine and oligoclonal lymphocyte profile. by Anna Kreutzman, Peter Rohon, Edgar Faber, Karel Indrak, Vesa Juvonen, Veli Kairisto, Jaroslava Voglová, Marjatta Sinisalo, Emília Flochová, Jukka Vakkila, Petteri Arstila, Kimmo Porkka, Satu Mustjoki

    Published 2011-01-01
    Get full text
    Article
  7. 7
    Clinical efficacy and safety of first‐line nilotinib or imatinib therapy in patients with chronic myeloid leukemia—Nationwide real life data

    Clinical efficacy and safety of first‐line nilotinib or imatinib therapy in patients with chronic myeloid leukemia—Nationwide real life data by Petra Belohlavkova, Daniela Zackova, Hana Klamova, Edgar Faber, Michal Karas, Lukas Stejskal, Eduard Cmunt, Olga Cerna, Ivana Jeziskova, Katerina Machova Polakova, Pavel Zak, Tereza Jurkova, Marika Chrapava, Jiri Mayer

    Published 2024-09-01
    Get full text
    Article
  8. 8
    Evaluation of 5‐year imatinib treatment of 458 patients with CP‐CML in routine clinical practice and prognostic impact of different BCR‐ABL cutoff levels

    Evaluation of 5‐year imatinib treatment of 458 patients with CP‐CML in routine clinical practice and prognostic impact of different BCR‐ABL cutoff levels by Hana Klamová, Kateřina Machová Poláková, Jan Mužík, Zdeněk Ráčil, Daniela Žáčková, Kateřina Steinerová, Michal Karas, Edgar Faber, Eva Demečková, Zuzana Michalovičová‐Sninská, Jaroslava Voglová, Ľudmila Demitrovičová, Eva Mikušková, Elena Tóthová, Juraj Chudej, Imrich Markuljak, Eduard Cmunt, Jana Moravcová, Dana Dvořáková, Kyra Michalová, Marie Jarošová, Markéta Marková Šťastná, Petr Cetkovský, Ladislav DuŠek, Vladimír Koza, Marek Trněný, Karel Indrák

    Published 2013-04-01
    Get full text
    Article
  9. 9
    P669: ANALYSIS OF FACTORS INFLUENCING THE DECISION TO STOP TKI TREATMENT IN CML PATIENTS IN DEEP MOLECULAR RESPONSE

    P669: ANALYSIS OF FACTORS INFLUENCING THE DECISION TO STOP TKI TREATMENT IN CML PATIENTS IN DEEP MOLECULAR RESPONSE by Lukas Semerad, Daniela Žáčková, Petra Belohlavkova, Jaroslava Voglova, Pavel Žák, Edgar Faber, Tomas Papajik, Ivana Skoumalova, Michal Karas, Pavel Jindra, Hana Klamová, Cyril Salek, Dana Srbová, Hana Zizkova, Lukas Stejskal, Olga Cerna, Eduard Cmunt, Petra Cicatkova, Anezka Kvetkova, Tomas Hornak, Ivana Jeziskova, Tomas Jurcek, Barbora Weinbergerová, Jirina Prochazkova, Katerina Machova Polakova, Adam Svobodnik, Radka Stepanova, Jiri Mayer

    Published 2023-08-01
    Get full text
    Article
  10. 10
    CCR7 as a novel therapeutic target in t-cell PROLYMPHOCYTIC leukemia

    CCR7 as a novel therapeutic target in t-cell PROLYMPHOCYTIC leukemia by Carlos Cuesta-Mateos, Patricia Fuentes, Alexandra Schrader, Raquel Juárez-Sánchez, Javier Loscertales, Tamara Mateu-Albero, Lorena Vega-Piris, Marina Espartero-Santos, Ana Marcos-Jimenez, Blanca Andrea Sánchez-López, Yaiza Pérez-García, Dennis Jungherz, Sebastian Oberbeck, Linus Wahnschaffe, Anna Kreutzman, Emma I. Andersson, Satu Mustjoki, Edgar Faber, Ana Urzainqui, Manuel Fresno, Kostantino Stamatakis, Arantzazu Alfranca, Fernando Terrón, Marco Herling, María Luisa Toribio, Cecilia Muñoz-Calleja

    Published 2020-10-01
    Get full text
    Article

Search Tools: